#AACR25 highlights #CommunityOnc: 1. #KN689: PeriOP/PostOP Pembro in H&N 2. NeoAdj Dostarlimab in dMMR solid tumors 3. #BeamionLung1: Zongertinib in HER2 NSCLC 4. **Bonus from #AUA25 #SunRISE1 in NMIBC #OncTwitter #MedTwitter OncoAlert 1/5

🔥 Devil’s Advocate Series: Should We Ditch Routine Cancer Surveillance? A new NEJM editorial says: ❌ No RCT benefit ❌ Lead-time illusion ❌ Scanxiety + $$$ ❌ Treating without improving survival? BUT… 🧬 What about ctDNA? 🎯 Can MRD-guided therapy open curative doors? 🧠 Do

ESMO 2024 Quick Take Insights: Prostate Cancer - #ARANOTE: Darolutamide + ADT shows significant rPFS benefits in mHSPC, offering a new treatment without docetaxel. - #PEACE3Study: Radium-223 + enzalutamide in mCRPC enhances rPFS & OS when used with bone protection in patients

Great Meeting! Nice to see/discuss with Friends&collegues#IKCS25. Lectures availableand worth to see: kidneycancer.swoogo.com/ikcseu25/84277…

Was great pleasure to see you all. Amazing discussions. Great to see so many options in bladder cancer now and improvements in survival. Félix Guerrero-Ramos Enrique Grande Roberto Iacovelli Nimira Alimohamed Patrizia Giannatempo

Tough 4 24h! Meetings on #GUCancers CHUV / Centre hospitalier universitaire vaudois @AVENUES25Lisboa @Knochen&KrebsBerlin25! Great discussions with great colleagues! Hope to meet U soon again! Syed A Hussain Roberto Iacovelli Enrique Grande @DrTianvanderheijden Paolo Gontero 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Ignacio H. Medrano

Amazing work and energy! philipp ivanyi . Was indeed a pleasure to catch up and learn from each other during these discussions over the weekend. Enrique Grande 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 @DrTianvanderheijden Paolo Gontero Roberto Iacovelli

GU Cancer Meetings Across Europe - philipp ivanyi oncodaily.com/url/292672 #Cancer #OncoDaily #Oncology #GlobalAwareness #FightAgainstCancer #CancerWorld #GUCancer

Published! Previliged to be a Part of SUNNIFORCAST! World largest ranomized trial on #non-ccRCC #kidney cancer deiven by Academia #MHH

7 years after the publication of the CARMENA study, we are back. Not only Deferred but even Upfront Cytoreductive Nephrectomy is making a comeback. For clinical practice: #mRCC with favourable prognostic factors - Upfront CRNE followed with immunotherapy. pubmed.ncbi.nlm.nih.gov/40221280/

Retifanlimab now U.S. FDA approved based off #POD1UM303: Ph III, recurrent or 1L metastatic squamous cell anal carcinoma, Carbo-Pac +/- Retifanlimab (anti-PD1): - ⬆️ mPFS: 9.3mos vs 7.4mos (HR 0.63) - ⬆️ mOS: 29.2mos vs 23mos (HR 0.70) - ORR 55.8% vs 44.2% #OncTwitter

This is one of the most amazing papers ever. Future Nobel?? NEJM drive.google.com/file/d/1Jfku5j…

philipp ivanyi We would like to inform you that your post has been published on OncoDaily.com. Thank you for sharing oncodaily.com/blog/philipp-i…

Where ever you‘re on the world an emotional reference point, remebers to the Great Periode of live were the Main Focus was #TheSimpsons. #ASCO25 Starts looking forward for Great Data an colleagues!

Congratulations Tian Zhang, MD, MHS et al. Great effort and excellent work. Real-world adaptive strategy meets real-life complexity. OS results awaited. awaited. #ASCO25 #cancer #oncology @oncoalert ASCO Kate Sears Toni Choueiri, MD Emre Yekedüz Neeraj Agarwal, MD, FASCO 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏

Quick takeaway from rapid oral bladder cancer: 🔸Bladder cancer is shifting toward chemo-free, immune- or targeted-based regimens. 🧬Molecular biomarkers (CCND1, PD-L1, Nectin-4) are driving personalization. 🔸Bladder preservation gains traction in MIBC with excellent cCR rates

Verpasst? Kein Problem! Die wichtigsten Erkenntnisse vom #ASCO25 gibt’s jetzt als Video on demand auf onkowissenTV ➡️ onkowissen.tv/beitraege/asco… Jozefina Casuscelli Christoffer.Gebhardt Peter J. Goebell Frank Griesinger Marc-Oliver Grimm Boris Hadaschik Andreas Hartkopf Ken Herrmann philipp ivanyi

Missed ASCO? Get the key insights now – fast & free 👉 high5oncologyTV: high5oncology.tv/meeting-covera… Stephen V Liu, MD Dr Riyaz Shah Frank Griesinger Martin Reck Noemi Reguart Lizza Hendriks Nicolas Girard denis Moro-Sibilot Hossein Borghaei, DO joaquim bellmunt Anders Bjartell Simon C Ignacio Duran

RCC updates from #ASCO25 are live on high5oncologyTV 🧬 Summarized in 100 seconds and thoroughly discussed by experts: high5oncology.tv/meeting-covera… Ignacio Duran Peter J. Goebell Hans Hammers philipp ivanyi Sumanta K. Pal, MD, FASCO Brian Rini, MD #KidneyCancer #RCC #RenalCellCarcinoma #ASCO2025

💥Neoadjuvant pembrolizumab has received the approval for PDL1 CPS≥1 head&neck SCC by FDA! 🛎️This will require quick CPS testings Not surprising seen this restricion for negative CPS, having only 16 patients in each arm of KEYNOTE689 without presenting their specific outcomes